Investigational drug · Phase 2
AZD5315
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Influenza A.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "AZD5315"
First trial start
2025
Sep 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD5315", any sponsor or status.
Conditions studied
As listed on its trial records.
- Influenza A
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD5315" as an intervention, largest first.
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07128615 · 405 participants · Start Sep 4, 2025 · Primary completion Jan 28, 2026
Drug: AZD4117; AZD5315 · For: Influenza A
Sites: Long Beach, California; Rolling Hills Estates, California; Miami Lakes, Florida · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Influenza A
- ZSP1273Phase 32 trials
Guangdong Raynovent Biotech Co., Ltd · Influenza A, Influenza a
- AZD4117Phase 21 trial
AstraZeneca · Influenza A
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.